[Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005102
Original Title: Cemiplimab (NSCLC, Kombination mit platinbasierter Chemotherapie)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Platinum
  • Antineoplastic Agents, Immunological
  • Cemiplimab
  • Carcinoma – Non-Small-Cell Lung
  • Benefit Assessment
  • NCT03409614
  • NCT02142738
  • NCT02220894
  • NCT02578680
  • NCT02775435
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.